Validation of newly derived polygenic risk scores for dementia in a prospective study of older individuals

Alzheimers Dement. 2023 Dec;19(12):5333-5342. doi: 10.1002/alz.13113. Epub 2023 May 12.

Abstract

Introduction: Recent genome-wide association studies identified new dementia-associated variants. We assessed the performance of updated polygenic risk scores (PRSs) using these variants in an independent cohort.

Methods: We used Cox models and area under the curve (AUC) to validate new PRSs (PRS-83SNP, PRS-SBayesR, and PRS-CS) compared with an older PRS-23SNP in 12,031 initially-healthy participants ≥70 years of age. Dementia was rigorously adjudicated according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria.

Results: PRS-83SNP, PRS-SBayesR, and PRS-CS were associated with incident dementia, with fully adjusted (including apolipoprotein E [APOE] ε4) hazard ratios per standard deviation (SD) of 1.35 (1.23-1.47), 1.37 (1.25-1.50), and 1.42 (1.30-1.56), respectively. The AUC of a model containing conventional/non-genetic factors and APOE was 74.7%. This was improved to 75.7% (p = 0.007), 76% (p = 0.004), and 76.1% (p = 0.003) with addition of PRS-83SNP, PRS-SBayesR, and PRS-CS, respectively. The PRS-23SNP did not improve AUC (74.7%, p = 0.95).

Conclusion: New PRSs for dementia significantly improve risk-prediction performance, but still account for less risk than APOE genotype overall.

Keywords: APOE gene; incident dementia; longitudinal study; polygenic risk score.

MeSH terms

  • Apolipoproteins E / genetics
  • Dementia* / genetics
  • Genetic Risk Score*
  • Genome-Wide Association Study
  • Humans
  • Prospective Studies
  • Risk Factors

Substances

  • Apolipoproteins E